American Association for Cancer Research
15357163mct190043-sup-215308_3_supp_5689557_pvp30n.doc (39 kB)

Supplementary Table S4 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Download (39 kB)
journal contribution
posted on 2023-04-03, 16:03 authored by Yin Huaqi, Qin Caipeng, Wang Qiang, Du Yiqing, Dai Xiang, Tang Xu, Zhang Xiaowei, Li Qing, Liu Shijun, Xu Tao

Univariable and multivariable analysis for ccRCC patients' overall survival using Cox's proportional hazards model


National Natural Science Foundation of China



The transcription factor SOX18, which was initially discovered as an activator of genetic transcription during embryogenesis, is now implicated in many diseases, including cancer, and is associated with the malignant tumor phenotype, angiogenesis, and lymphangiogenesis. However, the role of SOX18 in clear cell renal cell carcinoma (ccRCC) is not well understood. In the current study, SOX18 expression was evaluated in a 250 case–cohort of primary ccRCC tissues that included 103 cases of matched normal kidney tissues and 21 cases of metastatic tissues. Functional and mechanistic analyses were performed in cells that had SOX18 either overexpressed or silenced to evaluate the effects of SOX18 on cell function, the cellular response to cabozantinib, and SOX18-mediated molecular mechanisms. Our data revealed that upregulation and nuclear translocation of SOX18 promoted ccRCC carcinogenesis and metastasis. Elevated SOX18 expression was associated with advanced pathologic grades and TNM stages, as well as poor patient survival. SOX18 also regulated the cell cycle and the epithelial–mesenchymal transition to promote the malignant phenotype in ccRCC cells. The activation of EGF/EGFR and HGF/c-MET signaling in vitro and in vivo was induced by SOX18. Moreover, SOX18 activation bypassed the inhibitory effects of cabozantinib on cell proliferation, migration, and invasion. In conclusion, our data indicate that SOX18 may be a promising therapeutic target for ccRCC treatment.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager